Table 2.
Characteristics of patients from the PRODIGE17-ACCORD20-MEGA ancillary cohort.
| N = 80 | N (%) |
|---|---|
| Age (years) | |
| median | 65 |
| Sex | |
| male | 56 (70) |
| female | 24 (30) |
| Localization | |
| lower esophagus | 4 (5) |
| esogastric junction | 17 (21.5) |
| gastric body | 57 (71) |
| missing data | 2 (2.5) |
| Differentiation | |
| well | 8 (10) |
| moderate | 28 (35) |
| poor | 28 (35) |
| missing data | 16 (20) |
| Linitis/Diffuse type (Lauren’s classification) | |
| yes | 14 (17.5) |
| no | 45 (56) |
| mixed | 11 (14) |
| missing data | 10 (12.5) |
| Disease status | |
| local/locally advanced | 28 (35) |
| metastatic | 52 (65) |
| Tumor burden | |
| yes | 70 (87.5) |
| no (post-surgery patients) | 10 (12.5) |
| HER2 status | |
| positive | 11 (13.75) |
| negative | 61 (76.25) |
| missing data | 8 (10) |
| chemotherapy received by metastatic patients | |
| FOLFOX | 25 (48) |
| FOLFIRI | 6 (11.5) |
| FOLFOX HERCEPTIN | 3 (5.8) |
| OTHER | 8 (15.4) |
| NONE | 7 (13.5) |